TCM
SLN
TCG Crossover Management’s Silence Therapeutics SLN Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $17.6M | Hold |
3,033,560
| – | – | 2.01% | 21 |
|
|
2025
Q1 | $8.55M | Hold |
3,033,560
| – | – | 1.17% | 27 |
|
|
2024
Q4 | $20.9M | Hold |
3,033,560
| – | – | 2.04% | 23 |
|
|
2024
Q3 | $55.2M | Sell |
3,033,560
-261,790
| -8% | -$4.76M | 4.67% | 6 |
|
|
2024
Q2 | $62.6M | Hold |
3,295,350
| – | – | 6.53% | 4 |
|
|
2024
Q1 | $71.2M | Buy |
3,295,350
+1,190,475
| +57% | +$25.7M | 5.63% | 4 |
|
|
2023
Q4 | $36.6M | Hold |
2,104,875
| – | – | 4.05% | 12 |
|
|
2023
Q3 | $20.7M | Hold |
2,104,875
| – | – | 3.04% | 15 |
|
|
2023
Q2 | $11.6M | Hold |
2,104,875
| – | – | 1.9% | 15 |
|
|
2023
Q1 | $13.1M | Hold |
2,104,875
| – | – | 2.54% | 14 |
|
|
2022
Q4 | $32.1M | Hold |
2,104,875
| – | – | 5.67% | 6 |
|
|
2022
Q3 | $21.1M | Buy |
+2,104,875
| New | +$21.1M | 6.34% | 5 |
|